Akademik Veri Yönetim Sistemi
FABAD JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.49, sa.2, ss.435-448, 2024 (Scopus)
Globally, breast cancer stands as the most frequently diagnosed
cancer among women, with its incidence continually on the rise.
Conventional treatment methods for breast cancer have inherent
limitations. Consequently, the development of innovative treatment
approaches is imperative. Among these, targeted therapy strategies
have emerged as a critical point in contemporary clinical research,
significantly diversifying the treatment landscape for breast cancer in
recent years. The goals of these new treatment strategies are evolving
toward a future that can overcome the limitations of traditional
treatment methods, protect patients from side effects, and improve
patients’ survival rates and life quality. Nowadays, therapeutic
agents that bind to preferred targets are used based specifically on
various subtypes of breast cancer. The FDA-approved targeted
therapeutic agents—such as monoclonal antibodies, gene therapies,
immunotherapeutic cancer vaccines, and small molecule inhibitors,
are reviewed in this article.